Provided by Tiger Fintech (Singapore) Pte. Ltd.

Marinus Pharmaceuticals

0.5500
+0.0000
Volume:- -
Turnover:605.61K
Market Cap:30.35M
PE:-0.22
High:0.5500
Open:0.5500
Low:0.5500
Close:0.5500
Loading ...

BRIEF-Immedica To Acquire Biopharmaceutical Company Marinus Pharmaceuticals

Reuters
·
30 Dec 2024

Marinus Pharmaceuticals Inc - Immedica to Acquire Marinus for $0.55 per Share

THOMSON REUTERS
·
30 Dec 2024

Marinus Pharmaceuticals Inc - on Dec 6, Receives Nasdaq Notice for Minimum Bid Price Deficiency

THOMSON REUTERS
·
11 Dec 2024

Marinus Pharmaceuticals Price Target Maintained With a $2.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Nov 2024

Marinus Pharmaceuticals Faces Financial Turmoil Amidst Class Action Lawsuit

TIPRANKS
·
14 Nov 2024

Marinus Pharmaceuticals Reports Q3 Growth in ZTALMY Revenue

TIPRANKS
·
14 Nov 2024

Marinus Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
14 Nov 2024

Hold Rating on Marinus Pharmaceuticals Amid Strategic Uncertainty and TRUST-TSC Study Setbacks

TIPRANKS
·
14 Nov 2024

RBC Capital Reaffirms Their Hold Rating on Marinus (MRNS)

TIPRANKS
·
13 Nov 2024

Analysts Offer Insights on Healthcare Companies: Marinus (MRNS) and Medios AG (OtherMEDOF)

TIPRANKS
·
13 Nov 2024

Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates

Zacks
·
13 Nov 2024

Marinus Pharma Q3 EPS $(0.42) Misses $(0.41) Estimate, Sales $8.54M Miss $9.42M Estimate

Benzinga
·
13 Nov 2024

Marinus Pharmaceuticals reports Q3 EPS (42c), consensus (41c)

TIPRANKS
·
13 Nov 2024

Marinus Pharmaceuticals: Q3 Earnings Snapshot

Associated Press Finance
·
13 Nov 2024

Marinus Pharmaceuticals Inc: Narrowing Full Year 2024 Ztalmy Net Product Revenue Guidance to $33 to $34 Mln

THOMSON REUTERS
·
13 Nov 2024

Marinus Pharmaceuticals Inc Q3 Shr View $-0.41, REV View $9.4 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
13 Nov 2024